Pharvaris N.V.PHVSNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Financials Growth Insiders

Latest News

globenewswire.com

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

ZUG, Switzerland, March 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations for the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, which took place from February 27-March 2, 2026, in Philadelphia, PA.

defenseworld.net

Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have given a buy recommendation

globenewswire.com

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time

defenseworld.net

Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 904,318 shares, an increase of 22.2% from the December 31st total of 739,825 shares. Based on an average trading volume of 240,394 shares, the

globenewswire.com

Pharvaris Outlines 2026 Strategic Priorities

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Estimated cash runway into 1H2027 ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today outlined its strategic priorities for 2026. “The readout of Pharvaris' first pivotal Phase 3 study, RAPIDe-3, in December was the culmination of a decade of scientific rigor, operational and financial diligence, executional excellence, and, most importantly, community engagement and commitment,” said Berndt Modig, Chief Executive Officer of Pharvaris.

fool.com

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million.

zacks.com

Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.

seekingalpha.com

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

benzinga.com

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris N.V. (NASDAQ: PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.

globenewswire.com

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p

fool.com

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now

Increased Pharvaris stake by 500,000 shares, with a net position value change of $67.83 million Transaction represented 0.3% of General Atlantic, L.P.'s 13F reportable assets under management (AUM) Post-trade holding: 8,031,252 shares valued at $200.38 million The Pharvaris position now accounts for 6.0% of fund AUM, which places it outside the fund's top five holdings

seekingalpha.com

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout, supporting a high probability of success of 90%+ (author's judgement).

fool.com

Why Bain Capital Is Selling Shares of This Biotech Stock Now

Sold 122,106 shares of Pharvaris N.V, reducing position value by $21.23 million Post-trade holding: 3,181,275 shares valued at $79.37 million Position now accounts for 5.27% of AUM, ranking as the fund's 4th-largest holding

defenseworld.net

Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume After Analyst Upgrade

Shares of Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) saw unusually-strong trading volume on Monday after Morgan Stanley raised their price target on the stock from $34.00 to $37.00. Morgan Stanley currently has an overweight rating on the stock. Approximately 406,438 shares changed hands during mid-day trading, an increase of 247% from the previous session's

globenewswire.com

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026 Initiated CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Data presented at recent medical congresses, including final outcomes from the completed open-label extension phase of the Phase 2 CHAPTER-1 study, reinforce the potential of deucrictibant to differentiate through its efficacy and safety profile Strong financial position with cash and cash equivalents of €329 million as of September 30, 2025 ZUG, Switzerland, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “We remain on track to report data from the pivotal Phase 3 trial, RAPIDe-3, in the fourth quarter of 2025,” said Berndt Modig, Chief Executive Officer of Pharvaris.

globenewswire.com

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the 2025 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), including data from two oral presentations and six posters, which took place from November 6-10, 2025, in Orlando, Fla.

globenewswire.com

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting to be held from November 6-10, in Orlando, Florida.

seekingalpha.com

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Pharvaris N.V. (NASDAQ:PHVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Berndt A.

seekingalpha.com

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Pharvaris N.V. (NASDAQ:PHVS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 3:45 PM EDT Company Participants Peng Lu - Chief Medical Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst My name is Tiago Fauth.

seekingalpha.com

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Pharvaris N.V. (NASDAQ:PHVS ) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Wim Souverijns - Chief Commercial Officer Peng Lu - Chief Medical Officer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Okay.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance